Known industry-wide simply as the “montelukast diol,” this chiral quinoline-containing intermediate already carries the drug’s chlorostyryl-quinoline and hydroxypropyl-phenyl fragments joined together. It is converted to the corresponding mesylate and coupled with the mercaptoacetic-acid fragment to complete Montelukast Sodium.